SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Supriya Lifescience - Quaterly Results

20 May 2022 Evaluate
The sales surged to Rs. 1812.69 millions, up 37.21% for the March 2022 quarter as against Rs. 1321.07 millions during the corresponding quarter previous year.The Net Profit of the company registered a slight decline of -4.73% to Rs. 462.12  millions from Rs. 485.07 millions.Operating profit for the quarter ended March 2022 rose to 790.78 millions as compared to 686.68 millions of corresponding quarter ended March 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 1812.69 1321.07 37.21 5300.49 3912.45 35.48 5300.49 3912.45 35.48
Other Income 38.55 15.02 156.66 75.77 49.77 52.24 75.77 49.77 52.24
PBIDT 790.78 686.68 15.16 2215.62 1781.51 24.37 2215.62 1781.51 24.37
Interest 10.17 12.42 -18.12 41.98 40.80 2.89 41.98 40.80 2.89
PBDT 780.61 674.26 15.77 2173.64 1740.71 24.87 2173.64 1740.71 24.87
Depreciation 25.79 17.84 44.56 101.18 67.61 49.65 101.18 67.61 49.65
PBT 754.82 656.42 14.99 2072.46 1673.10 23.87 2072.46 1673.10 23.87
TAX 292.70 171.35 70.82 554.35 437.16 26.81 554.35 437.16 26.81
Deferred Tax 108.25 -3.50 -3192.86 32.46 6.94 367.72 32.46 6.94 367.72
PAT 462.12 485.07 -4.73 1518.11 1235.94 22.83 1518.11 1235.94 22.83
Equity 160.97 146.37 9.97 160.97 146.37 9.97 160.97 146.37 9.97
PBIDTM(%) 43.62 51.98 -16.07 41.80 45.53 -8.20 41.80 45.53 -8.20

Supriya Lifescience Share Price

632.40 4.40 (0.70%)
17-Apr-2026 11:39 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1681.15
Dr. Reddys Lab 1223.50
Cipla 1239.75
Zydus Lifesciences 945.55
Lupin 2315.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×